BioSpace News Archive

Axsome Therapeutics, Inc. is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist.

89bio, Inc. today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25.

Remix Therapeutics today announced an upcoming presentation introducing REM-422, the Company’s potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers.

Babson Diagnostics™, a science-first, health care technology company, announced that a key piece of its BetterWay™ Blood Testing ecosystem has achieved 510 clearance from the U.S. Food and Drug Administration.

Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”).

iSpecimen Inc. announced today the addition of several new suppliers, expanded relationships with existing suppliers and new offerings to increase access to critically important biospecimens for advancing biomedical research in oncology.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results of COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), were presented at the 34th International Symposium on ALS/MND by Jeremy Shefner, M.D., Ph.D., Lead Investigator of COURAGE-ALS, Professor of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix.

Solid Biosciences Inc. today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003.

AltruBio Inc. today announced the first patient enrolled for the Phase 2a clinical study of the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in ulcerative colitis (UC).

Cidara Therapeutics, Inc. today announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.